BridgeBio appoints Thomas Trimarchi as President and COO; Neil Kumar remains CEO

BridgeBio Pharma, Inc.

Thomas Trimarchi appointed President and COO effective July 23, 2024; Neil Kumar steps down as President but stays CEO and director.
Trimarchi previously served as Chief Product Officer since 2018; also board member of affiliate ML Bio Solutions (BBP-418 for LGMD2I/R9).
Newly created role to drive operational excellence, strategic planning, and centralize late-stage pipeline operations.
Trimarchi holds a Ph.D. in Molecular Oncology and Immunology from NYU; prior roles at Regeneron and Goldman Sachs.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Neil Kumar

President

BBIO · BridgeBio Pharma, Inc.

Effective: 2024-07-23
Successor: Thomas Trimarchi
Filed: July 23, 2024, 7:59 PM ET

Neil Kumar, Ph.D. stepped down as President

Appointed

Thomas Trimarchi

President and Chief Operating Officer

BBIO · BridgeBio Pharma, Inc.

Effective: 2024-07-23
Filed: July 23, 2024, 7:59 PM ET

Thomas Trimarchi was appointed as the Company’s President and Chief Operating Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Kumar changed role as President at BridgeBio Pharma, Inc..

Action: stepped down
Role: President

Exact text from the filing

Neil Kumar, Ph.D. stepped down as President

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Trimarchi was appointed as President and Chief Operating Officer at BridgeBio Pharma, Inc..

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

Thomas Trimarchi was appointed as the Company’s President and Chief Operating Officer

View on SEC.gov

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-033856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.